Menopause Hormone Therapy: ACOG’s 2026 Guide to Your Options

For two decades, women were told to tough out hot flashes. Learn to live with them. Buy a fan. The “just live with it” part of that advice is now officially out of date. Menopause hormone therapy is back at the center of the conversation, with the strongest backing it has had in years.

On October 15, 2026, the American College of Obstetricians and Gynecologists published its most complete guidance yet on managing menopause symptoms. The headline is blunt. It strongly recommends hormone therapy for hot flashes, night sweats, and the sleep problems they cause.

Here’s the thing. This is not a green light for everyone. It’s a green light for the right person, at the right time, on the right route. That is a decision you can walk into an appointment ready to have.

What the New Menopause Hormone Therapy Guidance Actually Says

Guidelines use grades, and ACOG used its strongest one: “strongly recommends.” In plain terms, that means the benefits clearly outweigh the risks for the right patient. It also means clinicians should be raising the option, not waiting for you to bring it up. Every recommendation is laid out in our menopause treatment guidelines explainer.

That is the real shift. For years, menopause hormone therapy was treated as a last resort, something you had to argue for. ACOG guideline co-author Bruce Pier, MD, put it plainly: “Unfortunately, misconceptions about the risks of hormone therapy have affected some clinicians’ willingness to prescribe it and some patients’ interest in using it.” That is the gap the guideline is trying to close.

The scale of the problem is not small. According to ACOG, 50% to 92% of women in menopause report hot flashes and night sweats. And 16% to 66% report sleep problems tied to menopause.

Who Is a Candidate for Menopause Hormone Therapy?

Menopause hormone therapy is not right for everyone. Eligibility comes down to two things. How much do your symptoms affect your life? And are hormones safe for you?

Shared decision making is the spine of the guideline. You and your clinician weigh your age, your medical history, and your baseline risk of heart disease, breast cancer, and blood clots. Your own goals belong in that conversation too. Sleep, work, mood, and how you want your days to feel all count.

One detail matters here. ACOG pairs estrogen with a progestogen for anyone who still has a uterus. That pairing protects the uterine lining. Estrogen alone is reserved for women who have had a hysterectomy.

The Timing Window Is About Starting, Not Stopping

Here is the number to remember. Before age 60, or within 10 years of your last period. That is when ACOG says to start. Start, not stop.

Most articles get this wrong. They treat 60 as a cutoff, or repeat a five-year limit that no longer exists. On November 10, 2025, the FDA removed the boxed warning from these products. It also dropped the old “lowest dose for the shortest time” instruction.

So what replaced it? Regular review. ACOG says the decision to continue should rest on a fresh look at your risk factors, not on a stopwatch. That is a very different talk from the one many women were given.

If you were told no years ago because of your age, or because of a warning printed on a box, you have a fair reason to ask again. Timing matters for the brain too. Our report on early menopause and Alzheimer’s risk explains why.

Why the Patch Keeps Coming Up

Route matters more than most people realize. Estrogen comes as a pill, patch, gel, spray, or vaginal product. They are not the same.

Transdermal forms, meaning patches, gels, and sprays, send hormone through your skin. They also appear to carry a lower risk of blood clots than pills. That difference shows up again and again in real-world data, though no large trial has confirmed it yet. It is the main reason many clinicians reach for a patch first.

Sleep is where the difference shows up in numbers. A 2022 review in the journal Menopause pooled 15 trials and 27,715 women. The patch and gel forms gave a bigger sleep benefit than pills. Estrogen plus progesterone helped sleep. Estrogen alone did not.

The same review found something worth knowing. Estradiol paired with micronized progesterone beat estradiol paired with a synthetic progestin. If you have a choice, ask about it.

If You Can’t or Won’t Use Hormones

This is where the 2026 guidance is genuinely new. ACOG strongly recommends SSRIs and SNRIs for hot flashes and depression, and strongly recommends neurokinin receptor antagonists for hot flashes and the sleep disruption they cause. Not as a consolation prize. As a real option.

Menopause hormone therapy is still the most effective single option. It is just no longer the only good one.

Antidepressants

SSRIs and SNRIs are strongly recommended for these symptoms. Only one, paroxetine, is FDA-approved specifically for hot flashes. Others are used off-label and still count as legitimate.

The Newer Non-Hormonal Drugs

A second family is newer: neurokinin receptor antagonists, often called NK antagonists. Two are approved. Fezolinetant arrived in 2023 and elinzanetant in 2025. In the OASIS-3 trial, elinzanetant cut daily hot flashes by about 1.6 more than placebo at 12 weeks.

Sleep and quality of life also trended better over the year. Those were secondary endpoints, though, and the trial was not built to test them. The 2026 network meta-analysis is the stronger evidence that it improves sleep. Reassuringly, it did not harm bone density or the uterine lining.

The trade-off is real, though. A 2026 meta-analysis found roughly double the dropout rate versus placebo. Headache, drowsiness, and fatigue were the usual culprits. If drowsiness is the problem, ask your clinician whether you can take it in the evening — that is a common practical adjustment, though it has not been tested head-to-head in trials.

Choosing between drug families is no longer a guess. A 2026 network meta-analysis found elinzanetant reduced hot flash frequency more than paroxetine, desvenlafaxine, and gabapentin. Cost and insurance often decide in practice, so ask about both.

Mood and Depression: Where the Hormone Evidence Stops Short

More than one-third of women in perimenopause and postmenopause report depressive symptoms, according to ACOG. So this is not a side note.

ACOG drew a careful line here, and it is worth quoting exactly. On using hormones to treat mood, the guideline states that “the available evidence is insufficient to recommend for or against the use of estrogen–progestogen or estrogen-only MHT for the treatment of menopause-related depressive symptoms.”

That is not a no. It is an honest “we don’t know,” and it changes what you should ask for. If your low mood tracks your hot flashes and broken sleep, and you do not meet the criteria for major depression, hormone therapy may help how you feel.

But if your dominant symptom is depression — loss of interest, hopelessness, not just irritability — ACOG says treat it as depression, with therapy, medication, or both. Menopause hormone therapy is not a substitute for that, and asking for depression treatment is not a failure.

What CBT and the Behavioral Options Actually Do

Not every effective option comes in a pill. ACOG conditionally recommends cognitive behavioral therapy, mindfulness-based interventions, regular exercise, clinical hypnosis, and acupuncture. Conditionally means the balance of benefits and harms is closer, or depends more on your own priorities — so it is worth discussing rather than simply prescribed.

ACOG says these can be used on their own, but are generally recommended alongside hormonal or non-hormonal medication. In practice that means they are not a consolation prize if you are on treatment — and they are still a legitimate option if you are not.

Here is what makes CBT worth a real look. A 2026 meta-analysis of 28 trials and 2,887 women found medium-to-large drops in how bothersome hot flashes and night sweats felt. Sleep quality improved a lot too. What barely moved was how often the flashes came.

That distinction is the whole point. CBT may not lower your count. It can lower how much your symptoms run your life.

The Honest Limits: What the Long-Term Data Still Say

Now the part that keeps this honest. Hormones are not risk-free, and the long-term data are not fuzzy.

Cochrane’s 2026 review pooled 24 trials and 45,660 women. Combined oral estrogen plus a synthetic progestin probably raised breast cancer risk by about 27%. It may also have raised stroke and clot risk. Estrogen-only therapy was not linked to an increased breast cancer risk in that data — if anything the signal ran slightly the other way, though the range of uncertainty does not rule out a small effect.

Two details matter more than the scary headlines. First, most of that evidence came from oral conjugated equine estrogens plus medroxyprogesterone acetate, in women whose average age was over 60. Second, only about 30% of participants were aged 50 to 59. That is the group most likely to seek treatment now.

None of that makes menopause hormone therapy risk-free. It tells you the risk depends on who you are, when you start, and which type you use. That is exactly why your own history has to be part of the decision. A 2025 network meta-analysis of 41 trials supports the flip side. Hormonal therapy still ranks highest for cutting both hot flash frequency and severity.

What Doesn’t Work: Soy, Herbs, and “Natural” Shortcuts

You will see soy isoflavones and herbal blends sold as hormone alternatives. ACOG is direct here. The evidence does not support their safety or their effectiveness. These products also are not regulated for purity or strength the way prescription drugs are.

Is there any signal at all? A little. A 2026 meta-analysis of nine trials found red clover isoflavones cut hot flash frequency versus placebo, with a small-to-moderate effect. That is far smaller than hormones or the newer non-hormonal drugs.

So eat soy foods if you enjoy them. Just don’t swap a prescription for a supplement and assume you have replaced treatment.

Before Your Appointment: Notes Worth Bringing

You do not need a perfect memory or a medical degree. You need notes.

Track two weeks of symptoms. Count hot flashes per day, night wakings, and how much they get in the way of work and sleep. Bring that list with you.

One more thing worth naming. ACOG’s guideline calls out a real gap in care. Data from the SWAN study show that Black women in midlife carry a heavier menopause symptom burden than white women, yet are less likely to receive treatment for it. So ask. Don’t wait for a clinician to bring it up first.

Bring your notes and your questions about menopause hormone therapy. A short list turns a rushed visit into a real talk.

The Bottom Line

The hormone therapy scare did not end because someone changed their mind. It ended because the evidence got better, the label changed, and the leading professional body for obstetrician-gynecologists in the US finally said the quiet part out loud.

If your sleep is being broken by night sweats, that is a medical problem with real treatments. If you also sit inside the timing window and have no conditions that rule hormones out, menopause hormone therapy is a reasonable thing to ask about.

And if it isn’t right for you, you still have options. Strong ones. Bring your notes, ask your questions, and keep the decision yours.